Topics

Advaxis and Personalis Enter Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

11:11 EST 12 Feb 2020 | Speciality Pharma Journal

PRINCETON, N.J. & MENLO PARK, Calif.–(BUSINESS WIRE)–Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration to leverage Personalis’ ImmunoID NeXT™ Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating …

Original Article: Advaxis and Personalis Enter Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

NEXT ARTICLE

More From BioPortfolio on "Advaxis and Personalis Enter Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...